Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
For example, if the patient had several abnormal nodes radiographically vs 1-2.
Answer from: Radiation Oncologist at Community Practice
Pre-chemo imaging if it shows 4 or more abnormal nodes (N2) then would offer RNI irrespective of response.
Sign in or Register to read more
26565
Related Questions
In a patient with T2N0 breast cancer with skin involvement s/p lumpectomy and negative margins, if you are offering whole breast radiation, would you bolus your tangent fields?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
How do you choose between ALND and RNI in the setting of LYMPHA or S-Lympha surgery?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
Would you offer APBI to a patient with very large breast anatomy and a small lumpectomy cavity after an oncoplastic closure?
Do you recommend high ozonated oil to prevent RT skin reaction during breast radiation?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
Does radiation therapy (ex. to the breast) in patients with CDK4 mutations increase the risk of developing melanoma?